
table of contents
This week's psychedelic articles
概況
There have been a series of regulatory and policy developments in the United States. At the federal level, the DEA has again attempted to grant Schedule I designation to five tryptamines, and the FDA has also made changes.サイケA public hearing was held regarding the future use of Derix. At the state level, there were reports that Oregon had reviewed its policy of raising fees related to psilocybin. In business terms, federal lobbying spending for Q2 2026 reached a record high. In cultural and social terms, an article delving into the reality surrounding PCP (Angel Dust) garnered attention.
Regulation/Policy
- DEA proposes reclassifying five types of tryptamine to Schedule I.
- The drugs targeted are 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET, and DiPT. The DEA had previously withdrawn a similar measure in 2022, making this its second attempt. MAPS has published a statement opposing the Schedule I designation, arguing that it would hinder research and criminalize personal use. They point out that DEA records do not show sufficient public harm to justify either of these actions. Building on the previous trend of designating DOIs and DOCs, MAPS is calling for the assurance of research feasibility.Referrer
- The FDA held a public hearing to clarify operational issues.
- The F.D.A.サイケA public hearing was held regarding the future use of Deriks. Speakers, randomly selected from approximately 200 applicants, were given two minutes each to speak, and a panel including representatives from the NIH, SAMHSA, and veterans' health listened to the opinions of nearly 80 people over approximately four hours. Training and qualifications, patient safety, access, and data standardization were among the main themes, and it was reported that most of the comments were positive. Eddie Jacobs of Johns Hopkins University mentioned that initial approval may not be far off and suggested that the initial operational design would have a long-term impact.Referrer
- Oregon to review plan to raise fees for psilocybin
- A quick report suggests that a state's plan to raise fees for its psilocybin program has "backpedaled." While details are limited, this move indicates that the state-level program design is still in the adjustment phase.Referrer
Business, Companies, and Funding
- Federal lobbying spending to reach record high in Q2 2026
- Spending by psychedelics-related development companies and non-profit organizations on federal lobbying will reach a record high in the second quarter of 2026. The total is estimated at just under $350,000, which, while still relatively modest, is seen as a sign of increasing industry involvement in policymaking.Referrer
Research/Society/Culture
- A collection of testimonies that reveal the true nature of PCP (phencyclidine).
- This article delves into the subculture surrounding PCP, often referred to as ketamine's "chemical cousin," exploring its image based on long-standing prejudices and anecdotes, through correspondence with users and various documents. The author also introduces the background of their co-authorship with VICE in 2021, demonstrating the multifaceted nature of the narratives surrounding PCP.Referrer
This week's highlights
- The DEA's rescheduling proposal is a key topic that will reignite debate over research continuity and the appropriateness of criminalization. MAPS's opposing statement clarifies the points.Referrer
- The FDA hearing brought to light implementation-related issues such as training and qualifications, safety, and access design. Notable aspects included the positive attitudes of many of the speakers and the presentation of expert opinions.Referrer
- Record-high lobbying spending and Oregon's fee review suggest that policymaking is dynamic. Continued attention will be paid to increased corporate and non-profit involvement and fine-tuning of state systems.Referrer

![Mail-order product: MDMA × MM Analog [For Research Use]](https://www.thch-vape.shop/html/user_data/assets/img/products/213_250x250.webp)


